TR 388 Mouse Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
ETHYLENETHIOUREA
NTP Experiment-Test: 05076-02 Report: PEIRPT05
Study Type: CHRONIC Date: 09/10/94
Route: DOSED FEED Time: 02:00:01
Facility: Battelle Columbus Laboratory
Chemical CAS #: 96-45-7
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05076-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENETHIOUREA Date: 09/10/94
Route: DOSED FEED Time: 02:00:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 0 PPM 100 PPM 333 PPM 333 PPM 333 PPM
0-0 10-0 1-1 0-3 3-3 10-3
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 29 50 50 50
Early Deaths
Moribund Sacrifice 9 4 6 6 11 9
Natural Death 6 8 2 1 3 5
Survivors
Terminal Sacrifice 34 37 21 42 34 36
Natural Death 1 1 1 2
Animals Examined Microscopically 50 50 29 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (49) (13) (8) (8) (16) (14)
Squamous Cell Carcinoma 1 (2%)
Gallbladder (41) (7) (8) (7) (12) (8)
Intestine Large, Cecum (44) (10) (8) (7) (14) (11)
Leiomyosarcoma 1 (2%)
Intestine Large, Colon (49) (12) (8) (9) (16) (12)
Leiomyosarcoma 1 (11%)
Intestine Small, Jejunum (46) (12) (10) (8) (19) (13)
Liver (50) (49) (28) (50) (50) (50)
Carcinoma, Metastatic, Islets, Pancreatic 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%) 4 (8%) 2 (4%) 1 (2%)
Hemangiosarcoma, Multiple 1 (2%) 1 (2%)
Hepatoblastoma 1 (2%) 1 (2%)
Hepatocellular Carcinoma 2 (4%) 5 (10%) 2 (7%) 14 (28%) 11 (22%) 9 (18%)
Hepatocellular Carcinoma, Multiple 15 (30%) 20 (40%) 14 (28%)
Hepatocellular Adenoma 2 (4%) 1 (2%) 2 (7%) 19 (38%) 17 (34%) 14 (28%)
Hepatocellular Adenoma, Multiple 14 (28%) 17 (34%) 21 (42%)
Histiocytic Sarcoma, Single 1 (4%) 2 (4%) 1 (2%) 2 (4%)
Mesentery (6) (2) (1) (1) (1)
Fibrosarcoma, Metastatic, Skin 1 (100%)
Hemangiosarcoma 1 (17%)
Lipoma 1 (17%)
Pancreas (50) (11) (8) (7) (16) (13)
Salivary Glands (50) (13) (8) (8) (15) (14)
Stomach, Forestomach (48) (15) (10) (11) (17) (14)
Squamous Cell Papilloma 1 (2%) 1 (7%) 1 (9%) 1 (6%)
Stomach, Glandular (48) (11) (8) (8) (15) (13)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05076-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENETHIOUREA Date: 09/10/94
Route: DOSED FEED Time: 02:00:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 0 PPM 100 PPM 333 PPM 333 PPM 333 PPM
0-0 10-0 1-1 0-3 3-3 10-3
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (13) (8) (8) (16) (14)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland (49) (13) (8) (8) (16) (12)
Capsule, Adenoma 1 (6%)
Adrenal Gland, Cortex (49) (13) (8) (8) (16) (11)
Adrenal Gland, Medulla (48) (13) (8) (8) (16) (11)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (49) (13) (8) (7) (15) (12)
Carcinoma 1 (8%)
Pituitary Gland (47) (48) (28) (49) (48) (47)
Pars Distalis, Adenoma 10 (21%) 11 (23%) 6 (21%) 19 (39%) 14 (29%) 26 (55%)
Pars Distalis, Carcinoma 1 (2%) 1 (4%)
Pars Intermedia, Adenoma 2 (7%) 1 (2%) 1 (2%)
Thyroid Gland (50) (49) (29) (50) (50) (49)
Follicular Cell, Adenoma 1 (2%) 1 (3%) 1 (2%) 3 (6%) 1 (2%)
Follicular Cell, Adenoma, Multiple 1 (2%) 2 (4%) 9 (18%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (49) (26) (20) (15) (24) (25)
Cystadenoma 1 (2%)
Cystadenoma, Papillary 1 (7%) 2 (8%)
Hemangioma 1 (4%)
Luteoma 1 (4%)
Uterus (48) (33) (13) (19) (20) (20)
Hemangiosarcoma 1 (5%)
Histiocytic Sarcoma, Single 1 (5%)
Leiomyosarcoma 1 (5%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (13) (8) (8) (16) (13)
Femoral, Hemangiosarcoma 1 (2%)
Femoral, Histiocytic Sarcoma, Single 1 (13%) 1 (13%)
Lymph Node (49) (18) (15) (19) (25) (19)
Page 3
NTP Experiment-Test: 05076-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENETHIOUREA Date: 09/10/94
Route: DOSED FEED Time: 02:00:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 0 PPM 100 PPM 333 PPM 333 PPM 333 PPM
0-0 10-0 1-1 0-3 3-3 10-3
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Mandibular, Hemangiosarcoma, Metastatic,
Liver 1 (4%)
Mandibular, Histiocytic Sarcoma, Single 1 (7%) 2 (11%) 1 (5%)
Mandibular, Sarcoma, Metastatic, Uncertain
Primary Site 1 (5%)
Pancreatic, Leiomyosarcoma, Metastatic,
Intestine Large 1 (5%)
Lymph Node, Mesenteric (14) (10) (8) (12) (14) (9)
Histiocytic Sarcoma, Single 1 (13%) 1 (8%) 1 (11%)
Lymph Node, Thoracic (2)
Spleen (50) (23) (13) (28) (31) (34)
Hemangiosarcoma 1 (2%) 1 (4%) 3 (11%) 1 (3%) 1 (3%)
Histiocytic Sarcoma, Single 1 (8%) 1 (4%) 2 (6%)
Thymus (39) (7) (4) (6) (12) (5)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (35) (13) (8) (8) (16) (11)
Adenocarcinoma 1 (3%) 1 (13%) 2 (25%) 2 (13%) 3 (27%)
Fibroadenoma 1 (3%) 1 (8%)
Skin (50) (13) (8) (8) (16) (15)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 1 (8%) 1 (7%)
Subcutaneous Tissue, Hemangiosarcoma 1 (2%) 1 (8%)
Subcutaneous Tissue, Sarcoma 1 (7%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (13) (9) (9) (16) (14)
Cranium, Osteosarcoma 1 (2%) 1 (8%)
Lumbar, Osteosarcoma 1 (7%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (13) (8) (8) (16) (14)
Carcinoma, Metastatic, Pituitary Gland 1 (2%)
Histiocytic Sarcoma, Single 1 (13%) 1 (7%)
Osteosarcoma, Metastatic, Bone 1 (8%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05076-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENETHIOUREA Date: 09/10/94
Route: DOSED FEED Time: 02:00:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 0 PPM 100 PPM 333 PPM 333 PPM 333 PPM
0-0 10-0 1-1 0-3 3-3 10-3
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (29) (50) (50) (50)
Adenocarcinoma, Metastatic, Harderian Gland 1 (3%)
Alveolar/Bronchiolar Adenoma 2 (4%) 3 (6%) 1 (3%) 7 (14%) 2 (4%) 5 (10%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 3 (6%) 2 (4%) 1 (2%) 1 (2%) 2 (4%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
Histiocytic Sarcoma, Single 1 (3%) 2 (4%) 1 (2%) 2 (4%)
Osteosarcoma, Metastatic, Bone 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (3) (3) (1) (4) (1) (1)
Adenocarcinoma 1 (33%) 1 (100%) 2 (50%)
Adenoma 2 (67%) 2 (67%) 1 (25%) 1 (100%) 1 (100%)
Bilateral, Adenoma 1 (25%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (12) (8) (11) (16) (15)
Histiocytic Sarcoma, Single 1 (9%)
Renal Tubule, Adenoma, Multiple 1 (2%)
Urinary Bladder (48) (12) (8) (9) (13) (11)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50) *(29) *(50) *(50) *(50)
Histiocytic Sarcoma 1 (3%) 2 (4%) 1 (2%) 2 (4%)
Lymphoma Malignant 1 (2%) 1 (2%)
Lymphoma Malignant Histiocytic 1 (2%) 1 (2%) 1 (3%) 1 (2%)
Lymphoma Malignant Lymphocytic 5 (10%) 2 (4%) 2 (7%) 2 (4%) 6 (12%) 3 (6%)
Lymphoma Malignant Mixed 14 (28%) 11 (22%) 5 (17%) 10 (20%) 17 (34%) 7 (14%)
Lymphoma Malignant Undifferentiated Cell 1 (2%) 2 (4%) 2 (4%) 3 (6%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05076-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENETHIOUREA Date: 09/10/94
Route: DOSED FEED Time: 02:00:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 0 PPM 100 PPM 333 PPM 333 PPM 333 PPM
0-0 10-0 1-1 0-3 3-3 10-3
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 36 33 20 49 49 50
Total Primary Neoplasms 59 53 26 124 126 131
Total Animals with Benign Neoplasms 17 19 9 42 40 44
Total Benign Neoplasms 22 23 12 65 59 81
Total Animals with Malignant Neoplasms 30 25 13 44 44 38
Total Malignant Neoplasms 37 30 14 59 67 50
Total Animals with Metastatic Neoplasms 2 2 1 3 1 1
Total Metastatic Neoplasm 2 3 1 3 1 2
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05076-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENETHIOUREA Date: 09/10/94
Route: DOSED FEED Time: 02:00:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 1000 PPM 1000 PPM
0-10 10-10
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50
Early Deaths
Natural Death 9 7
Moribund Sacrifice 10 14
Survivors
Natural Death 1
Terminal Sacrifice 30 29
Animals Examined Microscopically 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (39) (39)
Intestine Small, Jejunum (50) (48)
Liver (50) (50)
Hemangiosarcoma 2 (4%)
Hepatoblastoma 2 (4%) 8 (16%)
Hepatoblastoma, Multiple 1 (2%)
Hepatocellular Carcinoma 3 (6%) 3 (6%)
Hepatocellular Carcinoma, Multiple 44 (88%) 45 (90%)
Hepatocellular Adenoma 11 (22%) 10 (20%)
Hepatocellular Adenoma, Multiple 3 (6%) 7 (14%)
Histiocytic Sarcoma, Single 1 (2%) 2 (4%)
Mesentery (2) (1)
Pancreas (50) (50)
Salivary Glands (49) (50)
Histiocytic Sarcoma, Single 1 (2%)
Stomach, Forestomach (49) (50)
Stomach, Glandular (49) (50)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (49) (50)
Histiocytic Sarcoma, Single 1 (2%)
Adrenal Gland, Medulla (50) (50)
Pheochromocytoma Benign 1 (2%) 1 (2%)
Pituitary Gland (49) (47)
Pars Distalis, Adenoma 26 (53%) 24 (51%)
Page 7
NTP Experiment-Test: 05076-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENETHIOUREA Date: 09/10/94
Route: DOSED FEED Time: 02:00:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 1000 PPM 1000 PPM
0-10 10-10
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Thyroid Gland (50) (50)
Follicular Cell, Adenoma 4 (8%) 12 (24%)
Follicular Cell, Adenoma, Multiple 31 (62%) 26 (52%)
Follicular Cell, Carcinoma 8 (16%) 4 (8%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1)
Hepatocellular Carcinoma, Metastatic, Liver 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (50) (48)
Cystadenoma 2 (4%)
Cystadenoma, Papillary 1 (2%)
Granulosa Cell Tumor Benign 1 (2%)
Yolk Sac Carcinoma 1 (2%)
Uterus (48) (48)
Histiocytic Sarcoma, Single 1 (2%)
Polyp Stromal 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (49) (49)
Femoral, Histiocytic Sarcoma, Single 1 (2%)
Lymph Node (47) (49)
Mandibular, Histiocytic Sarcoma, Single 1 (2%) 2 (4%)
Mediastinal, Histiocytic Sarcoma, Single 2 (4%)
Renal, Histiocytic Sarcoma, Single 1 (2%)
Lymph Node, Mesenteric (4) (9)
Hepatocellular Carcinoma, Metastatic, Liver 1 (11%)
Histiocytic Sarcoma, Single 2 (22%)
Spleen (49) (50)
Hemangiosarcoma 1 (2%) 1 (2%)
Histiocytic Sarcoma, Single 1 (2%) 2 (4%)
Thymus (23) (33)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (33) (37)
Adenocarcinoma 1 (3%)
Fibroadenoma 1 (3%)
Skin (49) (50)
Page 8
NTP Experiment-Test: 05076-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENETHIOUREA Date: 09/10/94
Route: DOSED FEED Time: 02:00:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 1000 PPM 1000 PPM
0-10 10-10
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - cont
Squamous Cell Papilloma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%)
Subcutaneous Tissue, Mast Cell Tumor Benign 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50)
Alveolar/Bronchiolar Adenoma 4 (8%)
Alveolar/Bronchiolar Carcinoma 1 (2%)
Carcinoma, Metastatic, Thyroid Gland 1 (2%)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Hepatoblastoma, Metastatic, Liver 4 (8%)
Hepatocellular Carcinoma, Multiple,
Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 7 (14%) 5 (10%)
Histiocytic Sarcoma, Single 1 (2%) 2 (4%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (4) (3)
Adenocarcinoma 1 (33%)
Adenoma 1 (25%) 1 (33%)
Histiocytic Sarcoma, Single 1 (33%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50)
Renal Tubule, Adenocarcinoma 1 (2%)
Urinary Bladder (49) (49)
Page 9
NTP Experiment-Test: 05076-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENETHIOUREA Date: 09/10/94
Route: DOSED FEED Time: 02:00:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 1000 PPM 1000 PPM
0-10 10-10
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50)
Histiocytic Sarcoma 2 (4%) 2 (4%)
Lymphoma Malignant Histiocytic 1 (2%)
Lymphoma Malignant Lymphocytic 6 (12%) 5 (10%)
Lymphoma Malignant Mixed 5 (10%) 8 (16%)
Lymphoma Malignant Undifferentiated Cell 3 (6%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 10
NTP Experiment-Test: 05076-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENETHIOUREA Date: 09/10/94
Route: DOSED FEED Time: 02:00:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 1000 PPM 1000 PPM
0-10 10-10
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 48 50
Total Primary Neoplasms 158 173
Total Animals with Benign Neoplasms 41 43
Total Benign Neoplasms 82 88
Total Animals with Malignant Neoplasms 48 50
Total Malignant Neoplasms 76 85
Total Animals with Metastatic Neoplasms 10 9
Total Metastatic Neoplasm 10 11
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 11
NTP Experiment-Test: 05076-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENETHIOUREA Date: 09/10/94
Route: DOSED FEED Time: 02:00:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 0 PPM 100 PPM 333 PPM 333 PPM 333 PPM
0-0 10-0 1-1 0-3 3-3 10-3
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50 34 50 50 50
Early Deaths
Moribund Sacrifice 8 7 5 8 10 5
Natural Death 11 10 2 10 8 13
Accidently Killed 5
Survivors
Moribund Sacrifice 1
Natural Death 1 1 1
Terminal Sacrifice 30 27 25 31 32 30
Missing 1 1 1
Animals Examined Microscopically 50 49 33 50 50 49
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (50) (22) (8) (18) (15) (19)
Periesophageal Tissue, Sarcoma, Metastatic,
Skin 1 (13%)
Gallbladder (40) (12) (6) (10) (13) (11)
Fibrosarcoma, Metastatic, Skin 1 (8%)
Intestine Large, Colon (50) (21) (8) (17) (16) (16)
Intestine Large, Rectum (48) (19) (8) (17) (15) (16)
Squamous Cell Carcinoma 1 (2%)
Intestine Small, Ileum (44) (18) (7) (16) (14) (13)
Intestine Small, Jejunum (45) (20) (10) (18) (16) (18)
Adenocarcinoma 1 (2%) 1 (5%) 1 (10%)
Liver (49) (49) (33) (50) (47) (49)
Fibrosarcoma, Metastatic, Skin 1 (2%) 1 (2%)
Hemangioma 1 (2%)
Hemangiosarcoma 2 (4%) 1 (2%) 1 (3%) 2 (4%) 1 (2%)
Hemangiosarcoma, Multiple 1 (2%) 1 (2%) 2 (4%)
Hepatoblastoma 1 (3%) 1 (2%) 3 (6%)
Hepatoblastoma, Multiple 1 (2%)
Hepatocellular Carcinoma 9 (18%) 6 (12%) 3 (9%) 11 (22%) 7 (15%) 12 (24%)
Hepatocellular Carcinoma, Multiple 4 (8%) 2 (4%) 1 (3%) 8 (16%) 8 (17%) 7 (14%)
Hepatocellular Adenoma 8 (16%) 2 (4%) 4 (12%) 12 (24%) 12 (26%) 14 (29%)
Hepatocellular Adenoma, Multiple 3 (6%) 4 (8%) 2 (6%) 4 (8%) 3 (6%) 6 (12%)
Histiocytic Sarcoma 1 (2%) 1 (3%) 1 (2%) 2 (4%) 1 (2%)
Mesentery (6) (1) (1) (1)
Fibrosarcoma, Metastatic, Skin 1 (100%)
Histiocytic Sarcoma 1 (100%)
Pancreas (48) (20) (7) (17) (15) (17)
Pharynx (1)
Squamous Cell Papilloma 1 (100%)
Page 12
NTP Experiment-Test: 05076-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENETHIOUREA Date: 09/10/94
Route: DOSED FEED Time: 02:00:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 0 PPM 100 PPM 333 PPM 333 PPM 333 PPM
0-0 10-0 1-1 0-3 3-3 10-3
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
Salivary Glands (50) (21) (8) (19) (15) (17)
Sarcoma, Metastatic, Skin 1 (13%)
Stomach, Forestomach (49) (24) (7) (17) (16) (22)
Squamous Cell Papilloma 2 (8%) 2 (9%)
Stomach, Glandular (48) (21) (7) (17) (15) (18)
Tooth (5)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (23) (8) (19) (15) (19)
Adenocarcinoma, Metastatic, Uncertain
Primary Site 2 (9%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland (50) (21) (8) (18) (15) (18)
Spindle Cell, Subcapsular, Adenoma 1 (2%)
Spindle Cell, Subcapsular, Adenoma, Multiple 1 (2%)
Adrenal Gland, Medulla (50) (21) (8) (18) (15) (18)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (48) (20) (7) (17) (15) (17)
Pituitary Gland (44) (42) (28) (42) (41) (45)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (50) (46) (33) (49) (47) (48)
Follicular Cell, Adenoma 1 (2%) 1 (3%) 1 (2%) 1 (2%) 2 (4%)
Follicular Cell, Carcinoma 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (49) (22) (8) (18) (15) (19)
Preputial Gland (2) (2) (1) (2) (4) (3)
Carcinoma 1 (25%)
Prostate (50) (22) (8) (18) (15) (19)
Seminal Vesicle (4) (2) (1) (1) (1)
Testes (50) (22) (8) (20) (14) (19)
Interstitial Cell, Adenoma 1 (5%)
____________________________________________________________________________________________________________________________________
Page 13
NTP Experiment-Test: 05076-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENETHIOUREA Date: 09/10/94
Route: DOSED FEED Time: 02:00:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 0 PPM 100 PPM 333 PPM 333 PPM 333 PPM
0-0 10-0 1-1 0-3 3-3 10-3
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Blood (1)
Bone Marrow (49) (21) (8) (18) (13) (19)
Lymph Node (48) (25) (15) (22) (20) (22)
Axillary, Fibrosarcoma, Metastatic, Skin 1 (5%)
Axillary, Sarcoma, Metastatic 1 (4%)
Deep Cervical, Sarcoma, Metastatic, Skin 1 (7%)
Inguinal, Hepatoblastoma, Metastatic, Liver 1 (5%)
Mandibular, Histiocytic Sarcoma 1 (5%)
Lymph Node, Mesenteric (14) (11) (7) (4) (8) (6)
Fibrosarcoma, Metastatic, Skin 1 (13%)
Histiocytic Sarcoma 1 (14%) 1 (13%)
Spleen (49) (25) (12) (21) (24) (24)
Hemangiosarcoma 1 (2%) 1 (4%)
Histiocytic Sarcoma 1 (4%)
Thymus (29) (11) (4) (11) (11) (11)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (26) (14) (23) (25) (26)
Schwannoma Malignant 1 (4%)
Squamous Cell Carcinoma 1 (4%)
Squamous Cell Papilloma 1 (4%)
Subcutaneous Tissue, Fibroma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 1 (2%) 5 (19%) 4 (29%) 6 (26%) 6 (24%) 8 (31%)
Subcutaneous Tissue, Fibrosarcoma, Multiple 1 (4%)
Subcutaneous Tissue, Fibrous Histiocytoma 1 (2%) 1 (7%) 2 (8%)
Subcutaneous Tissue, Histiocytic Sarcoma 1 (4%)
Subcutaneous Tissue, Neurofibrosarcoma 1 (4%) 1 (4%)
Subcutaneous Tissue, Sarcoma 2 (4%) 1 (4%) 1 (7%) 1 (4%) 3 (12%)
Subcutaneous Tissue, Schwannoma Malignant 1 (7%) 1 (4%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (21) (8) (19) (15) (19)
____________________________________________________________________________________________________________________________________
Page 14
NTP Experiment-Test: 05076-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENETHIOUREA Date: 09/10/94
Route: DOSED FEED Time: 02:00:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 0 PPM 100 PPM 333 PPM 333 PPM 333 PPM
0-0 10-0 1-1 0-3 3-3 10-3
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (49) (33) (50) (47) (49)
Adenocarcinoma, Metastatic, Uncertain
Primary Site 1 (2%)
Alveolar/Bronchiolar Adenoma 4 (8%) 6 (12%) 10 (30%) 6 (12%) 11 (23%) 8 (16%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 1 (2%) 3 (6%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 1 (3%) 1 (2%) 6 (12%)
Alveolar/Bronchiolar Carcinoma, Multiple 1 (2%) 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hepatoblastoma, Metastatic, Liver 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 10 (20%) 1 (2%) 1 (3%) 2 (4%) 1 (2%) 1 (2%)
Histiocytic Sarcoma 2 (4%) 1 (2%)
Nose (50) (21) (8) (19) (16) (18)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (4) (1) (3) (3) (1) (3)
Adenocarcinoma 1 (33%)
Adenoma 1 (25%) 1 (100%) 3 (100%) 2 (67%) 1 (100%) 1 (33%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (23) (11) (21) (17) (19)
Hepatocellular Carcinoma, Metastatic, Liver 1 (5%) 1 (6%)
Urinary Bladder (49) (20) (8) (17) (15) (16)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(49) *(33) *(50) *(50) *(49)
Histiocytic Sarcoma 1 (2%) 1 (3%) 1 (2%) 2 (4%) 1 (2%)
Lymphoma Malignant Histiocytic 1 (2%) 1 (2%)
Lymphoma Malignant Lymphocytic 4 (8%) 1 (2%) 1 (3%) 3 (6%) 1 (2%) 2 (4%)
Lymphoma Malignant Mixed 2 (4%) 3 (6%) 3 (9%) 2 (4%) 6 (12%) 6 (12%)
Lymphoma Malignant Undifferentiated Cell 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 15
NTP Experiment-Test: 05076-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENETHIOUREA Date: 09/10/94
Route: DOSED FEED Time: 02:00:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 0 PPM 100 PPM 333 PPM 333 PPM 333 PPM
0-0 10-0 1-1 0-3 3-3 10-3
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 35 28 25 40 39 48
Total Primary Neoplasms 56 38 40 65 72 90
Total Animals with Benign Neoplasms 16 14 15 23 25 30
Total Benign Neoplasms 22 17 20 27 30 36
Total Animals with Malignant Neoplasms 28 19 16 31 30 41
Total Malignant Neoplasms 34 21 20 38 42 54
Total Animals with Metastatic Neoplasms 10 3 2 3 2 4
Total Metastatic Neoplasm 10 8 4 3 4 5
Total Animals with Malignant Neoplasms 2
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 16
NTP Experiment-Test: 05076-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENETHIOUREA Date: 09/10/94
Route: DOSED FEED Time: 02:00:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 1000 PPM 1000 PPM
0-10 10-10
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 50 50
Early Deaths
Moribund Sacrifice 14 10
Natural Death 13 15
Survivors
Terminal Sacrifice 22 24
Natural Death 1 1
Animals Examined Microscopically 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Jejunum (44) (40)
Liver (50) (49)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hemangiosarcoma 1 (2%) 2 (4%)
Hemangiosarcoma, Multiple 1 (2%)
Hepatoblastoma 4 (8%) 7 (14%)
Hepatoblastoma, Multiple 2 (4%) 3 (6%)
Hepatocellular Carcinoma 3 (6%) 5 (10%)
Hepatocellular Carcinoma, Multiple 42 (84%) 40 (82%)
Hepatocellular Adenoma 4 (8%) 9 (18%)
Hepatocellular Adenoma, Multiple 5 (10%) 6 (12%)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Sarcoma, Metastatic 1 (2%)
Mesentery (5) (3)
Pancreas (45) (47)
Salivary Glands (50) (49)
Stomach, Glandular (48) (44)
Tooth (4) (1)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hemangioma 2 (4%)
Hepatocellular Carcinoma, Metastatic, Liver 1 (2%)
____________________________________________________________________________________________________________________________________
Page 17
NTP Experiment-Test: 05076-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENETHIOUREA Date: 09/10/94
Route: DOSED FEED Time: 02:00:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 1000 PPM 1000 PPM
0-10 10-10
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (50) (49)
Adrenal Gland, Medulla (50) (49)
Pheochromocytoma Benign 1 (2%) 2 (4%)
Pituitary Gland (41) (39)
Pars Distalis, Adenoma 8 (20%) 4 (10%)
Pars Intermedia, Adenoma 1 (2%)
Thyroid Gland (50) (49)
Follicular Cell, Adenoma 8 (16%) 11 (22%)
Follicular Cell, Adenoma, Multiple 18 (36%) 22 (45%)
Follicular Cell, Carcinoma 8 (16%)
Follicular Cell, Carcinoma, Multiple 5 (10%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (49) (49)
Preputial Gland (2) (1)
Prostate (47) (49)
Seminal Vesicle (2)
Testes (50) (49)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Blood (1)
Bone Marrow (49) (47)
Lymph Node (47) (48)
Pancreatic, Sarcoma, Metastatic, Skin 1 (2%)
Lymph Node, Mesenteric (7) (5)
Histiocytic Sarcoma 1 (14%)
Spleen (48) (47)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Hemangiosarcoma 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (49) (50)
Basosquamous Tumor Malignant 1 (2%)
Squamous Cell Carcinoma 1 (2%)
Subcutaneous Tissue, Fibrosarcoma 5 (10%) 5 (10%)
Page 18
NTP Experiment-Test: 05076-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENETHIOUREA Date: 09/10/94
Route: DOSED FEED Time: 02:00:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 1000 PPM 1000 PPM
0-10 10-10
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM - cont
Subcutaneous Tissue, Sarcoma 1 (2%)
Subcutaneous Tissue, Sarcoma, Multiple 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
None
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (49)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (49)
Alveolar/Bronchiolar Adenoma 4 (8%) 6 (12%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (4%)
Alveolar/Bronchiolar Carcinoma 2 (4%)
Carcinoma, Metastatic, Thyroid Gland 1 (2%) 2 (4%)
Carcinoma, Metastatic, Uncertain Primary Site 1 (2%)
Fibrosarcoma, Metastatic, Skin 1 (2%) 1 (2%)
Hepatoblastoma, Metastatic, Liver 2 (4%) 3 (6%)
Hepatoblastoma, Metastatic, Uncertain
Primary Site 1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver 11 (22%) 21 (43%)
Histiocytic Sarcoma 1 (2%)
Nose (50) (49)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1)
Pinna, Hemangioma 1 (100%)
Harderian Gland (18) (6)
Adenocarcinoma 1 (17%)
Adenoma 4 (22%) 1 (17%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (49)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Renal Tubule, Adenoma 1 (2%)
Urinary Bladder (48) (48)
Page 19
NTP Experiment-Test: 05076-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENETHIOUREA Date: 09/10/94
Route: DOSED FEED Time: 02:00:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 1000 PPM 1000 PPM
0-10 10-10
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(50) *(50)
Histiocytic Sarcoma 1 (2%) 1 (2%)
Lymphoma Malignant Lymphocytic 3 (6%) 2 (4%)
Lymphoma Malignant Mixed 3 (6%) 3 (6%)
Lymphoma Malignant Undifferentiated Cell 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 20
NTP Experiment-Test: 05076-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC ETHYLENETHIOUREA Date: 09/10/94
Route: DOSED FEED Time: 02:00:01
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 1000 PPM 1000 PPM
0-10 10-10
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 47 47
Total Primary Neoplasms 136 143
Total Animals with Benign Neoplasms 36 41
Total Benign Neoplasms 59 61
Total Animals with Malignant Neoplasms 46 46
Total Malignant Neoplasms 77 82
Total Animals with Metastatic Neoplasms 17 27
Total Metastatic Neoplasm 21 30
Total Animals with Malignant Neoplasms 1 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 21
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------
--multipart-boundary
Content-type: text/plain
Range: bytes 127105-127105/127105
--multipart-boundary--